Human Reproduction Update Advance Access originally published online on January 5, 2007
Human Reproduction Update 2007 13(3):249-264; doi:10.1093/humupd/dml058
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Why does ovarian surgery in PCOS help? Insight into the endocrine implications of ovarian surgery for ovulation induction in polycystic ovary syndrome
1 Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, VU University Medical Center 2 Medical Library, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
3 To whom correspondence should be addressed at: Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands. E-mail: m.hendriks{at}vumc.nl
 |
Abstract |
|---|
 TOP Abstract IntroductionMaterials and methodsResultsDiscussionConclusionAcknowledgementsReferences |
|---|
Polycystic ovary syndrome (PCOS) is a complex disorder with heterogeneity of clinical and endocrine features. Ovarian surgery for ovulation induction has been used in the management of clomiphene citrate-resistant anovulatory women with PCOS. Various types of ovarian surgery have been employed (wedge resection, electrocautery, laser vaporization, multiple ovarian biopsies and others) and all procedures result in an altered endocrine profile after surgery. The mechanism behind the reversal of endocrinological dysfunction in PCOS after ovarian surgery remains incompletely understood. This review scans the literature systematically to identify the endocrine changes after ovarian surgery in PCOS, in order to glean some knowledge of the mechanism involved. After ovarian surgery in PCOS, a rapid reduction in serum levels of all ovarian hormones is seen, in combination with increased serum levels of pituitary hormones. Folliculogenesis is then initiated and ovarian hormone production increases, synchronically with a reduction of pituitary hormones. Continuation of follicle growth in subsequent cycles after ovarian surgery occurs in an environment with less androgens and lower LH and FSH levels compared with pretreatment levels. The endocrine changes found after ovarian surgery in PCOS women seem to be governed by the ovaries themselves. Rapid reduced secretion of all ovarian hormones restores feedback to the hypothalamus and pituitary, resulting in appropriate gonadotrophin secretion. Initiation of follicular development seems to be induced by increasing FSH levels following a reduction of the follicle excess and (intra-ovarian) androgen levels. Additionally, anti-Müllerian hormone and gonadotrophin surge attenuating factor probably have a role in the endocrine changes.
Key words: endocrinology / infertility / ovulation induction / polycystic ovary syndrome / surgery
|
Introduction |
|---|
|
TOPAbstractIntroductionMaterials and methodsResultsDiscussionConclusionAcknowledgementsReferences |
|---|
Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility (Adams et al., 1986
) and is classically characterized by clinical symptoms of hyperandrogensim (hirsutism and acne) and oligo- or amenorrhoea. The presentation of PCOS symptoms is very heterogeneous, varies from mild to severe and has a wide spectrum. The confusion caused by this heterogeneity of clinical and endocrine features regarding the definition of PCOS will hopefully be settled by the adoption of the recent Rotterdam consensus (2004). Common endocrine abnormalities in PCOS include chronic high luteinising hormone (LH) levels (Berger et al., 1975; Panidis et al., 2005), hyperandrogenism (Wild et al., 1985; Kumar et al., 2005), hyperinsulinaemia, insulin resistance (Dunaif et al., 1989) and dyslipidoproteinaemia (Wild et al., 1985; Wild, 2002). These endocrine disturbances interfere with folliculogenesis, are (partly) responsible for oligo- or anovulation and are likely to constitute an increased risk for cardiovascular diseases and diabetes (Legro et al., 1999; Elting et al., 2001). In spite of years of research, PCOS remains incompletely understood.
Ovarian surgery for ovulation induction restores the menstrual cycle in the majority of patients suffering from PCOS and favourably changes their endocrine profile (Cohen, 1996). Seventy years after the first report of successful surgical ovarian intervention in PCOS (Stein and Leventhal, 1935), the mechanism behind the reversal of endocrinological dysfunction after ovarian surgery remains unclear. Surgical ovarian intervention for PCOS is sparely used at the present time, as acceptable ovulation and pregnancy rates are achieved using clomiphene citrate, metformin and gonadotrophins. However, some women remain anovulatory or cannot be successfully treated medically, and ovarian surgery becomes an option.
Several surgical approaches for restoring ovulation in women with PCOS have been studied over the years, for example classical wedge resection, multiple ovarian biopsies, laser vaporization and electrocautery. All types of ovarian surgery share a common goal of creating ovarian damage and from an endocrine point of view can be seen as equivalent procedures (Cohen, 1996). A clear distinction has to be made, however, between ovarian drilling to induce ovulation and more extensive ovarian drilling to prevent ovarian stimulation syndrome. The latter method requires more profound ovarian destruction, done by using a lot of power to ‘pepper pot’ the ovaries, whereas the methods for ovulation induction attempt to use the lowest possible dose to achieve the desired effect. Within this review, only the studies with ovarian surgery for ovulation induction are discussed.
The cause for reversal of the endocrinological dysfunction after ovarian surgery in PCOS is unclear. Many theories have been proposed for the cause of the re-establishment of menstrual cycles after ovarian surgery. Originally, the removal of a mechanical barrier has been postulated (Katz et al., 1978; Ben Shlomo et al., 1998) and reducing the size of the ovary was thought to allow gonadotrophins to act more effectively after the ovarian surgery (Katz et al., 1978). Others have suggested that surgery may cause increased blood flow to the ovaries, resulting in increased delivery of gonadotrophins (Cohen, 1996; Takeuchi et al., 2002). Reduction of androgens after ovarian surgery causes lower peripheral aromatization to estrogens and could theoretically result in restoring feedback to the hypothalamus and pituitary (Felemban et al., 2000; Takeuchi et al., 2002). More recent theories include gonadotrophin surge attenuating factor (GnSAF, also called gonadotrophin surge inhibiting factor: GnSIF). GnSAF is a hormone produced by the ovaries (Messinis et al., 1991) and its function lies in regulating and suppressing LH secretion by reducing pituitary sensitivity (Fowler et al., 2003). A deficiency of GnSAF in PCOS patients has been hypothesized as the cause of elevated LH levels (Balen and Jacobs, 1991; de Koning et al., 2001). Ovarian surgery could cause increased insulin-like growth factor-I (IGF-I) production, which interacts with follicle stimulating hormone (FSH) and results in follicular development. Follicle growth causes increased GnSAF production, and GnSAF subsequently suppresses LH secretion (Balen and Jacobs, 1994). Another suggested mechanism is reduced inhibin levels after ovarian surgery leading to increased FSH levels (Al Ojaimi, 2004). Less is known about the importance of Anti-Müllarian hormone (AMH) regarding ovarian surgery in PCOS. AMH is an ovarian product and a local inhibitor of FSH action (Durlinger et al., 2001, 2002) and may play a role in restoration of ovulation after ovarian surgery.
No extended review has yet been published to augment the endocrine implications of ovarian surgery and this review combines the existing literature (systematically searched) to identify essential endocrine changes after ovarian surgery in PCOS in order to glean some knowledge of the mechanism involved and further insight into the pathophysiology of PCOS.
|
Materials and methods |
|---|
|
TOPAbstractIntroductionMaterials and methodsResultsDiscussionConclusionAcknowledgementsReferences |
|---|
A systematic literature search was conducted in PubMed (January 2006), Embase.com and the Cochrane Library-Wiley (December 2005) databases. Three groups of search terms were used in every possible spelling, as synonyms, acronyms, key- or text words and these groups were combined with an ‘AND’-operator. (i) PCOS, (ii) surgical interventions: (electro)cautery, (electro)coagulation, diathermy, drilling, laparoscopic ovarian drilling (LOD), laser, biopsy, excision, wedge, endoscopy, laparoscopy, surgery and (iii) hormones: LH, FSH, testosterone, gonadotrophins, gonadotrophin releasing hormone (GnRH), prolactin, androgens, androstenedione, dehydroepiandrosterone (sulphate) (DHEA(S)), dihydrotestosterone (DHT), sex hormone-binding globulin (SHBG), estrogen, progesterone, anti-Miillarian hormone (AMH), gonadotrophin surge-inhibiting factor/gonodotrophin surge-attenuating factor (GnSIF/GnSAF), hormones, endocrinology. Case reports and animal-studies were excluded. The full search strategy can be requested from the corresponding author.
A trial was eligible for inclusion if it was a publication in English and the treatment consisted of an ovarian surgery procedure to induce or facilitate ovulation induction in subfertile women with established PCOS, in combination with endocrine results before and after surgery. Study description of characteristics of PCOS subject had to be in accordance with the Rotterdam consensus (2004) criteria. Two reviewers selected the eligible studies, when discordance existed, a uniform decision was made by re-evaluating the study. A total of 63 papers were eligible for this review. Figures shown in this review represent weighted average hormonal values on indicated days, constructed by weighing the mean value of an individual study with their group size (Hazewinkel, 2002) and were constructed when multiple studies were available at different time points to summarize the effect of the surgery. The figures represent an estimate of endocrine changes after ovarian surgery and are shown without units, due to limitations of combining data from different studies with different hormonal assay methodology.
|
Results |
|---|
|
TOPAbstractIntroductionMaterials and methodsResultsDiscussionConclusionAcknowledgementsReferences |
|---|
Ovarian hormones
Testosterone and androstenedione
Androgens are frequently and classically elevated in PCOS, with or without clinical symptoms (DeVane et al., 1975; Kumar et al., 2005). The potent androgens testosterone and androstenedione are both secreted by the ovary and the adrenal gland (Burger, 2002) and testosterone is additionally derived from peripheral production (Burger, 2002). Considerable amounts of testosterone are bound to SHBG, only the unbound proportion is biologically active (free) testosterone (Burger, 2002).
Testosterone
Serum testosterone concentrations in PCOS patients decreased after ovarian surgery from post-operative day 1 (Aakvaag and Gjonnaess, 1985; Gjonnaess and Norman, 1987; Greenblatt and Casper, 1987; van der Weiden and Alberda, 1987; van der Weiden et al., 1989; Tasaka et al., 1990; Utsunomiya et al., 1990; Kovacs et al., 1991; Gadir et al., 1992; Campo et al., 1993; Naether et al., 1993; Liguori et al., 1996; Parsanezhad et al., 2005). One study showed a non-significant decrease one day after surgery (Kojima et al., 1989). One study showed increased testosterone values three hours after surgery preceding a rapid decrease on the first postoperative day (Judd et al., 1976). Testosterone concentrations reached a nadir around 3 days after surgery (Greenblatt and Casper, 1987; Campo et al., 1993; Liguori et al., 1996), followed by a small increase, but never reaching pretreatment values.
In the first days, weeks and years following ovarian surgery, testosterone levels remained low in the majority of the studies (Vejlsted and Albrechtsen, 1976; Aakvaag and Gjonnaess, 1985; Greenblatt and Casper, 1987; van der Weiden and Alberda, 1987; Sumioki et al., 1988; van der Weiden et al., 1989; Armar et al., 1990; Gadir et al., 1990; Keckstein et al., 1990; Tasaka et al., 1990; Utsunomiya et al., 1990; Kovacs et al., 1991; Rossmanith et al., 1991; Abdel et al., 1993; Campo et al., 1993; Naether et al., 1993; Tiitinen et al., 1993; Verhelst et al., 1993; Alborzi, 1994; Liguori et al., 1996; Taskin et al., 1996; Anttila et al., 1998; Gjonnaess, 1998, 1999; Kaaijk et al., 1999; Soliman et al., 2000; Wu et al., 2000, 2004; Zullo et al., 2000; Alborzi et al., 2001; Amer et al., 2002a; Asada et al., 2002; Takeuchi et al., 2002; Amin et al., 2003; Duleba et al., 2003; Malkawi et al., 2003; Parsanezhad et al., 2003; Al Ojaimi, 2004; Api et al., 2005; Kucuk and Kilic-Okman, 2005; Malkawi and Qublan, 2005; Parsanezhad et al., 2005). A few studies found no change in testosterone concentrations after ovarian surgery (Campo et al., 1983; Kojima et al., 1989; Szilagyi et al., 1990; Farhi et al., 1995; Fukaya et al., 1995; Farquhar et al., 2002). Although most studies did not find differences in baseline and/or post-treatment testosterone values between post-treatment ovulatory and non-ovulatory women, between pregnant and non-pregnant women or between obese versus lean patients (Abdel et al., 1993; Campo et al., 1993; Duleba et al., 2003; Al Ojaimi, 2004; Wu et al., 2004; Parsanezhad et al., 2005), some studies did find lower (Aakvaag and Gjonnaess, 1985; Amer et al., 2003b; Api et al., 2005; Hayashi et al., 2005; Kucuk and Kilic-Okman, 2005) or higher (Farhi et al., 1995) testosterone concentrations pre- and/or post-operatively in post-treatment ovulatory PCOS women.
A dose/‘puncture’ response relationship was found in one study, showing lower testosterone levels after surgery when using more punctures. This relationship was seen using low numbers of punctures per ovary (Amer et al., 2003a), but was not found in a study using more punctures (Malkawi and Qublan, 2005).
Regularly ovulating controls undergoing diagnostic laparoscopy or laparoscopic tubal ligation showed no testosterone change in the first days to weeks after surgery in two studies (Greenblatt and Casper, 1987; Liguori et al., 1996). However, other studies found a testosterone decrease after surgery in controls, although less marked than in PCOS women (Gjonnaess and Norman, 1987; Utsunomiya et al., 1990; Parsanezhad et al., 2005).
Overall, profound reduction of testosterone was seen from the first day after ovarian surgery. Testosterone levels reached a nadir around the third post-operative day and thereafter increased gradually, without reaching pre-operative values (Figure 1A). Responders to ovarian surgery seemed to have comparable pre- and post-treatment testosterone concentrations compared with non-responders (Figure 1B), although some studies gave conflicting results. The reduction of testosterone seemed to be dose dependent (the more tissue destruction, the lower the testosterone levels after surgery), although this relationship was only found using low numbers of punctures per ovary and a maximal testosterone reduction was quickly reached.
|
Regularly ovulating controls showed a slight decline of androgens after laparoscopic surgery, but this was less marked than that in PCOS women (Figure 1A).
Androstenedione
Serum androstenedione levels decreased significantly in the first days after treatment in most studies (Judd et al., 1976; Aakvaag and Gjonnaess, 1985; Gjonnaess and Norman, 1987; Greenblatt and Casper, 1987; Sumioki et al., 1988; Kojima et al., 1989; van der Weiden et al., 1989; Armar et al., 1990; Sakata et al., 1990; Szilagyi et al., 1990; Campo et al., 1993; Liguori et al., 1996; Zullo et al., 2000), although two studies found a non-significant reduction (van der Weiden and Alberda, 1987; Utsunomiya et al., 1990). Androstenedione levels during the surgical procedure increased in both PCOS women (Judd et al., 1976; Armar et al., 1990) and regularly ovulating controls (Judd et al., 1976). A nadir was reached 2–4 days after treatment (Judd et al., 1976; Greenblatt and Casper, 1987; Armar et al., 1990; Sakata et al., 1990; Campo et al., 1993; Liguori et al., 1996).
Week(s) to years after ovarian surgery, androstenedione levels in PCOS remained low, although there was a tendency to increase slightly over time (Judd et al., 1976; Aakvaag and Gjonnaess, 1985; Greenblatt and Casper, 1987; van der Weiden and Alberda, 1987; Sumioki et al., 1988; Kojima et al., 1989; van der Weiden et al., 1989; Armar et al., 1990; Keckstein et al., 1990; Sakata et al., 1990; Rossmanith et al., 1991; Campo et al., 1993; Szilagyi et al., 1993; Tiitinen et al., 1993; Verhelst et al., 1993; Taskin et al., 1996; Anttila et al., 1998; Gjonnaess, 1998, 1999; Wu et al., 2000; Amer et al., 2002a, 2003a; Malkawi et al., 2003; Malkawi and Qublan, 2005). A few studies showed no androstenedione change following ovarian surgery (Utsunomiya et al., 1990; Kovacs et al., 1991; Cibula et al., 2000). Post-treatment ovulatory women showed lower androstenedione levels prior to and after surgery compared with non-responders (Aakvaag and Gjonnaess, 1985). A dose/‘puncture’ response relationship was found in one study, showing lower androstenedione levels after surgery when using more punctures. Comparable to testosterone, the dose response relationship for androstenedione was seen using low numbers of punctures per ovary (Amer et al., 2003a), but was not found in a study using more punctures (Malkawi and Qublan, 2005).
Regularly ovulating controls showed no change of androstenedione levels after surgery (Judd et al., 1976; Utsunomiya et al., 1990; Liguori et al., 1996; Amer et al., 2002a), although one study found decreased levels after treatment (Gjonnaess and Norman, 1987).
To summarize, reduction of androstenedione in PCOS was seen from the first day after ovarian surgery, but during the ovarian surgery elevated androstenedione levels were found. Androstenedione levels reached a nadir around the fourth post-operative day, and thereafter androgen values increased gradually (Figure 2). PCOS patients responding to ovarian surgery seem to have lower pre- and post-treatment androstenedione values compared with non-responders (no figure due to limited numbers of studies). Reduction of androstenedione could be dose dependent, although this relationship was only found using low numbers of punctures per ovary. Regularly ovulating controls showed no change of androstenedione after laparoscopic surgery (Figure 2).
|
Estradiol
Ovarian granulosa cells produce estrogens in response to FSH stimulation (Havelock et al., 2004
). Women with PCOS frequently have chronic stable estrogen levels due to insufficient follicle growth.
Estradiol concentrations remained stable in the first days following ovarian surgery in PCOS women in most studies (Aakvaag and Gjonnaess, 1985; Gjonnaess and Norman, 1987; Sumioki et al., 1988; Kojima et al., 1989; van der Weiden et al., 1989; Sakata et al., 1990; Szilagyi et al., 1990; Utsunomiya et al., 1990; Abdel et al., 1993), although decreased levels were also found (Judd et al., 1976; Tanaka et al., 1978; Greenblatt and Casper, 1987). Early and mid follicular estradiol concentrations weeks after surgery were comparable to pretreatment levels (van der Weiden et al., 1989; Gadir et al., 1990; Sakata et al., 1990; Tasaka et al., 1990; Verhelst et al., 1993; Wu et al., 2004; Kucuk and Kilic-Okman, 2005; Kandil and Selim, 2005) or were decreased (Rossmanith et al., 1991; Szilagyi et al., 1993).
Late follicular, peri-ovulatory and luteal estrogen levels were higher than before ovarian surgery, especially in responders (Aakvaag and Gjonnaess, 1985; Kojima et al., 1989; Verhelst et al., 1993; Gjonnaess, 1998). Many studies compared pre- and post-treatment estradiol measurements without mentioning the cycle days. These studies will not be discussed here, because results cannot be interpreted.
Regularly ovulating controls showed no estradiol change following surgery (Gjonnaess and Norman, 1987).
Overall, estradiol decreased slightly in the first days after surgery, followed by an increase approximately three weeks after treatment (Figure 3A). The early follicular estradiol levels in subsequent cycles were slightly decreased compared with pretreatment values. Peri-ovulatory and luteal estradiol concentrations were increased, especially in responders (Figure 3B).
|
Inhibins
Inhibins are produced by granulosa cells and production is stimulated by FSH, and inhibins, in turn, inhibit FSH secretion (Laven and Fauser, 2004
). Inhibin B is mainly produced by pre- and small antral follicles and concentrations are highest in the midfollicular phase (Laven and Fauser, 2004). Women with PCOS have inhibin B levels within the normal range (Magoffin and Jakimiuk, 1998; Norman et al., 2001; Cortet-Rudelli et al., 2002; Welt et al., 2002), in spite of many small follicles. It has been speculated that inhibin levels in PCOS are relatively suppressed by LH and insulin (Welt et al., 2002).
Three studies reported inhibin levels before and after ovarian surgery. Pre-operatively inhibin B levels on cycle day 5 were higher than in regularly ovulating controls and no pattern of regular pulsatility was seen (Lockwood et al., 1998). A rapid decrease of inhibin post-operatively followed by a subsequent rise (maximum at 3 weeks) was found by Kovacs et al. (1991) (although this study did not define its PCOS population used), and initiation of inhibin B pulsatility was seen after ovarian surgery (Lockwood et al., 1998).
Two studies showed lower inhibin B levels in the early follicular phase, 1–3 months after bilateral drilling or diathermy (Lockwood et al., 1998; Kandil and Selim, 2005) whereas no significant change was seen after unilateral drilling (Kandil and Selim, 2005).
Inhibin levels seem to decrease rapidly after ovarian surgery, followed by a subsequent rise and restoration of inhibin pulsatility. Inhibin levels rose 3–5 weeks after ovarian surgery. Early follicular phase levels in subsequent cycles after ovarian surgery showed lower inhibin levels. Due to limited studies measuring inhibin after surgery, it was not possible to compose a figure.
Progesterone
Progesterone is produced by luteinized granulosa cells under LH stimulation (Havelock et al., 2004).
Progesterone concentrations remained stable for up to 2 weeks after ovarian surgery and in subsequent follicular phases (Aakvaag and Gjonnaess, 1985; Gjonnaess and Norman, 1987; Verhelst et al., 1993; Wu et al., 2004). One study showed a decline of progesterone 8 days after surgery in ovulatory women (Armar et al., 1990). Approximately 3 weeks after ovarian surgery and in following luteal phases, progesterone levels rose and were higher than pretreatment values (Aakvaag and Gjonnaess, 1985; Verhelst et al., 1993; Gjonnaess, 1998, 1999).
Progesterone levels in regularly ovulating controls did not show changes after surgery (Gjonnaess and Norman, 1987).
Ovarian surgery does not seem to influence progesterone levels directly after the procedure (Figure 4A and 4B). Weeks after the treatment, progesterone levels rose temporarily in patients responding to surgery and returned to pretreatment levels in subsequent follicular phases.
|
Anti-Müllerian hormone
AMH is an ovarian product, a marker of ovarian reserve (van Rooij et al., 2002
, 2005) and is a local inhibitor of FSH action (Durlinger et al., 2001, 2002). Ovarian production of AMH is higher in PCOS patients compared with women with regular menstrual cycles (Cook et al., 2002; Pigny et al., 2006), probably due to an excess of antral follicles (Jonard and Dewailly, 2004). So far, no studies have been published about the possible AMH changes after ovarian surgery in PCOS.
Luteinising hormone
LH stimulates androstenedione production by ovarian theca cells (Havelock et al., 2004) and is responsible for ovulation and luteinization. Chronically elevated LH concentrations are common and characteristic of women with PCOS (van Santbrink et al., 1997) and are (partly) responsible for the problems associated with this syndrome.
The day after ovarian surgery, LH concentrations in PCOS women increased in most studies (Gjonnaess and Norman, 1987; Greenblatt and Casper, 1987; Sakata et al., 1990; Tasaka et al., 1990; Naether et al., 1993; Liguori et al., 1996), although no (significant) change (Judd et al., 1976; Kojima et al., 1989; van der Weiden et al., 1989; Utsunomiya et al., 1990; Abdel et al., 1993; Campo et al., 1993) and an LH decrease were also found (Parsanezhad et al., 2005). Subsequently, LH levels decreased and remained low (with the exception of peri-ovulatory peaks) for years after surgery (Tanaka et al., 1978; Aakvaag and Gjonnaess, 1985; Gjonnaess and Norman, 1987; Greenblatt and Casper, 1987; Sumioki et al., 1988; van der Weiden et al., 1989; Armar et al., 1990; Gadir et al., 1990, 1992; Sakata et al., 1990; Tasaka et al., 1990; Rossmanith et al., 1991; Szilagyi et al., 1993; Tiitinen et al., 1993; Alborzi, 1994; Farhi et al., 1995; Fukaya et al., 1995; Liguori et al., 1996; Taskin et al., 1996; Anttila et al., 1998; Gjonnaess, 1998, 1999; Soliman et al., 2000; Wu et al., 2000, 2004; Zullo et al., 2000; Alborzi et al., 2001; Amer et al., 2002a, b, 2003a, b; Takeuchi et al., 2002; Amin et al., 2003; Duleba et al., 2003; Malkawi et al., 2003; Parsanezhad et al., 2003; Al Ojaimi, 2004; Kamel et al., 2004; Api et al., 2005; Kucuk and Kilic-Okman, 2005; Malkawi and Qublan, 2005; Parsanezhad et al., 2005). A few studies found unchanged LH levels weeks to months after surgery or increased LH values (mostly peri-ovulatory measurements) (Judd et al., 1976; Kojima et al., 1989; Szilagyi et al., 1990; Utsunomiya et al., 1990; Kovacs et al., 1991; Campo et al., 1993; Naether et al., 1993; Verhelst et al., 1993; Cibula et al., 2000; Asada et al., 2002).
Baseline LH values were higher in women who responded to surgery (Al Ojaimi, 2004; Hayashi et al., 2005) and in lean women (Wu et al., 2004), whereas others found no differences (Duleba et al., 2003) or lower LH values in responders (Api et al., 2005). The magnitude of the LH-decrease after surgery was higher in PCOS responders (ovulatory or pregnant) compared with non-responders (Aakvaag and Gjonnaess, 1985; Abdel et al., 1993; Jamal, 2000; Amer et al., 2003b; Parsanezhad et al., 2003; Al Ojaimi, 2004; Api et al., 2005; Hayashi et al., 2005).
A dose/‘puncture’ dependency was found, showing a more pronounced increase in LH levels after surgery when using more punctures. This relationship was seen using a small number of punctures per ovary (Amer et al., 2002b, 2003a), but this was not shown with more punctures (Malkawi and Qublan, 2005). After surgery, the LH amplitude decreased while the frequency remained stable (Sumioki et al., 1988; Rossmanith et al., 1991).
Regularly ovulating controls did not show LH change after surgery (Judd et al., 1976; Gjonnaess and Norman, 1987; Utsunomiya et al., 1990; Amer et al., 2002a; Parsanezhad et al., 2005).
Thus LH concentrations showed a transient increase the day after ovarian surgery in PCOS, followed by a gradual decrease (Figure 5A). Weeks to years after ovarian surgery, LH levels remained low, with the exception of peri-ovulatory peaks. Lower LH pulse amplitude seems to cause the lower LH levels, while the LH pulse frequency remained stable. Minimal ovarian damage was needed to lower the LH concentrations and a possible dose response relationship was seen. Both responders to ovarian surgery and non-responders showed an LH increase the day after surgery. PCOS women responding to ovarian surgery showed a more pronounced decline of LH levels in the early follicular phase after the procedure compared with non-responders (Figure 5B).
|
Follicle stimulating hormone
FSH stimulates granulosa cell production of estradiol, inhibin B and GnSAF (Messinis et al., 1991
; Havelock et al., 2004; Laven and Fauser, 2004). Increasing pituitary FSH production during the early follicular phase allows the growth of a follicle cohort. Anovulation in PCOS is thought to be partly due to a relative intrinsic inhibition of FSH action. The follicular arrest can be reversed by increasing the amount of FSH by FSH supplementation or stimulation of endogenous FSH production by clomiphene citrate administration. Pituitary FSH secretion is selectively suppressed by inhibin A and B (Laven and Fauser, 2004).
FSH levels rose in the first days after ovarian surgery in women with PCOS (Greenblatt and Casper, 1987; Sakata et al., 1990; Tasaka et al., 1990; Naether et al., 1993; Liguori et al., 1996; Parsanezhad et al., 2003), although some studies found no (significant) change (Judd et al., 1976; Gjonnaess and Norman, 1987; Kojima et al., 1989; van der Weiden et al., 1989; Utsunomiya et al., 1990; Campo et al., 1993; Parsanezhad et al., 2005).
In the first weeks after surgery, FSH concentrations declined to levels comparable to baseline values (Judd et al., 1976; Tanaka et al., 1978; Aakvaag and Gjonnaess, 1985; Gjonnaess and Norman, 1987; Greenblatt and Casper, 1987; Sumioki et al., 1988; Kojima et al., 1989; Armar et al., 1990; Sakata et al., 1990; Szilagyi et al., 1990, 1993; Tasaka et al., 1990; Kovacs et al., 1991; Campo et al., 1993; Naether et al., 1993; Tiitinen et al., 1993; Verhelst et al., 1993; Alborzi, 1994; Farhi et al., 1995; Fukaya et al., 1995; Liguori et al., 1996; Anttila et al., 1998; Soliman et al., 2000; Wu et al., 2000, 2004; Zullo et al., 2000; Amer et al., 2002a, 2003a, b; Takeuchi et al., 2002; Duleba et al., 2003; Malkawi et al., 2003; Kandil and Selim, 2005; Kucuk and Kilic-Okman, 2005; Malkawi and Qublan, 2005; Parsanezhad et al., 2005), whereas others found increased (van der Weiden et al., 1989; Gadir et al., 1990; Utsunomiya et al., 1990; Rossmanith et al., 1991; Abdel et al., 1993; Taskin et al., 1996; Amer et al., 2002b; Amin et al., 2003; Parsanezhad et al., 2003; Al Ojaimi, 2004; Kamel et al., 2004; Api et al., 2005) or decreased (Szilagyi et al., 1990; Gjonnaess, 1998, 1999; Alborzi et al., 2001) FSH values after ovarian surgery.
A dose/‘puncture’ dependency was not found (Amer et al., 2003a; Malkawi and Qublan, 2005), although one study showed a possible trend towards higher FSH levels when using more punctures (Amer et al., 2002b). FSH pulse frequency and amplitude did not change after the treatment (Sumioki et al., 1988; Rossmanith et al., 1991).
PCOS responders showed a more pronounced increase in FSH in the first days after surgery compared with non-responders (Aakvaag and Gjonnaess, 1985; Armar et al., 1990; Abdel et al., 1993; Campo et al., 1993). In most studies, FSH values in the weeks after surgery were comparable between responders and non-responders and the initial difference seen after surgery was lost (Jamal, 2000; Amer et al., 2003b; Al Ojaimi, 2004; Api et al., 2005), although one study found elevated FSH in responders (Parsanezhad et al., 2003) and another in non-responders (Hayashi et al., 2005).
Regularly ovulating controls showed no FSH change after surgery (Judd et al., 1976; Gjonnaess and Norman, 1987; Utsunomiya et al., 1990; Amer et al., 2002a; Parsanezhad et al., 2005).
Overall, FSH concentrations increased in the first days after ovarian surgery, with a more pronounced elevation in responders (Figure 6A and 6B). Following this FSH elevation, the levels returned gradually to pre-operative values and the initial difference shortly after surgery between responders and non-responders was lost (Figure 6B). FSH pulsatility did not change after surgery.
|
Prolactin
Prolactin is mainly secreted by the anterior pituitary and secretion is under the tonic inhibition of dopamine. Prolactin has a diurnal variation and various factors like estrogens and (surgical) stress stimulate prolactin secretion (Tyson et al., 1972
; Sassin et al., 1973; Brandt et al., 1976). Studies with large PCOS populations showed average prolactin levels within the (high) normal range (Balen et al., 1995; Hernandez et al., 2000). In spite of normal prolactin levels in PCOS, the reaction to a dopamine receptor antagonist (metoclopramide) is less than in ovulatory controls, suggesting a low dopamine hypothalamic tone (Minakami et al., 1988; Hernandez et al., 2000).
After surgery, prolactin levels rose on the first day in both PCOS patients and in ovulatory controls (Gjonnaess and Norman, 1987; van der Weiden et al., 1989; Parsanezhad et al., 2005). Prolactin concentrations were not altered weeks to years after the procedure in the majority of the studies (van der Weiden et al., 1989; Gadir et al., 1990; Szilagyi et al., 1990; Verhelst et al., 1993; Gjonnaess, 1998; Alborzi et al., 2001; Duleba et al., 2003; Al Ojaimi, 2004; Wu et al., 2004; Kucuk and Kilic-Okman, 2005). One study showed a decline in prolactin after the ovarian procedure (Alborzi, 1994), another study an increase in prolactin up to 10 weeks after ovarian surgery (Parsanezhad et al., 2005). Parsanezhad et al. (2005) showed that the majority of the women remaining anovulatory after ovarian surgery were hyperprolactinaemic 6–10 weeks after surgery. Prolactin response to dopaminergic blockade by metoclopramide was increased after ovarian surgery (Szilagyi et al., 1993).
A transient prolactin elevation after surgery was seen in both PCOS patients and in regularly ovulatory controls. Ovarian surgery does not seem to influence basal prolactin levels weeks to months after the procedure, although dopaminergic inhibition of prolactin seems to increase as indicated by the increased response to metoclopramide.
Gonadotrophin releasing hormone challenge test
The sensitivity and priming of the pituitary to gonadotrophin releasing hormone (GnRH or LHRH) can be measured by the magnitude of FSH and LH response to GnRH administration. Patients with PCOS have a higher LH response to GnRH compared with ovulatory controls (Heineman et al., 1984). This suggests that in women with PCOS the pituitary is already primed. The cause of this increased sensitivity of the pituitary in PCOS is unclear. It has been suggested that the low concentrations of the ovarian hormone GnSAF may be responsible for this priming. GnSAF normally antagonizes the priming (Fowler et al., 1990; Dafopoulos et al., 2004).
Ovarian surgery diminished pituitary LH response to GnRH administration in the first weeks after ovarian surgery in PCOS (Tanaka et al., 1978; Sumioki et al., 1988; Keckstein et al., 1990; Mio et al., 1991; Rossmanith et al., 1991; Campo et al., 1993; Fukaya et al., 1995). Only on the first day after surgery was the LH response to GnRH found to be increased (Gjonnaess and Norman, 1987).
Dehydroepiandrosterone
Dehydroepiandrosterone (DHEA) and DHEA-sulphate (DHEAS) act as inactive precursor steroids for peripheral conversion into more potent androgens (Burger, 2002; Labrie et al., 2005). They are predominantly of adrenocortical origin and are frequently elevated in PCOS (DeVane et al., 1975; Kumar et al., 2005). Due to its adrenocortical origin, DHEAS is used as a marker for adrenal androgen production (Kumar et al., 2005).
In the first days after ovarian surgery, DHEA(S) levels decreased in half of the studies (Gjonnaess and Norman, 1987; Szilagyi et al., 1990; Utsunomiya et al., 1990; Liguori et al., 1996), whereas the other studies showed no significant change (Aakvaag and Gjonnaess, 1985; Naether et al., 1993; Cibula et al., 2000; Parsanezhad et al., 2005).
Weeks to months after ovarian surgery, DHEAS and/or DHEA levels were comparable with pre-operative values in the majority of the studies (Vejlsted and Albrechtsen, 1976; Campo et al., 1983; Aakvaag and Gjonnaess, 1985; Gjonnaess and Norman, 1987; Sumioki et al., 1988; Armar et al., 1990; Szilagyi et al., 1990; Utsunomiya et al., 1990; Kovacs et al., 1991; Rossmanith et al., 1991